BDBM375276 US10597387, Compound (I-1)::US9908872, Compound (I-1)

SMILES CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(NC(=O)c3cncc(c3)-c3cccs3)c2)CC1

InChI Key InChIKey=LNQHMSWBIGYWSY-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 375276   

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375276(US9908872, Compound (I-1) | US10597387, Compound (...)
Affinity DataIC50: 22.9nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375276(US9908872, Compound (I-1) | US10597387, Compound (...)
Affinity DataIC50: 7.40nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetHexokinase-4(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375276(US9908872, Compound (I-1) | US10597387, Compound (...)
Affinity DataIC50: 8.21E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375276(US9908872, Compound (I-1) | US10597387, Compound (...)
Affinity DataIC50: 22.9nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375276(US9908872, Compound (I-1) | US10597387, Compound (...)
Affinity DataIC50: 7.40nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375276(US9908872, Compound (I-1) | US10597387, Compound (...)
Affinity DataIC50: 8.21E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2020
Entry Details
Go to US Patent